<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03214796</url>
  </required_header>
  <id_info>
    <org_study_id>ALB-INFUS</org_study_id>
    <nct_id>NCT03214796</nct_id>
  </id_info>
  <brief_title>Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status</brief_title>
  <acronym>ALB-INFUS</acronym>
  <official_title>Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of albumin infusion on oxidative albumin&#xD;
      modification, on plasma thiol status and on albumin binding capacity for DS in patients who&#xD;
      routinely receive albumin infusion for various indications and to relate these findings with&#xD;
      neurohumoral parameters, bacterial products such as endotoxin, and neutrophil function&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Albumin infusion has been shown to improve outcome in spontaneous bacterial peritonitis, to&#xD;
      reverse hepatorenal syndrome combined with vasoconstrictors, and to prevent post-paracentesis&#xD;
      circulatory dysfunction. These beneficial effects are associated with hemodynamic improvement&#xD;
      reflected by neurohumoral changes such as a decrease in plasma renin activity .&#xD;
&#xD;
      Albumin is a multifunctional protein. Its biological functions include maintenance of oncotic&#xD;
      pressure, solubilization and transport of hydrophobic substances, antioxidant function via&#xD;
      its free sulfhydryl group at cysteine-34, metal binding at its N-terminus, immunomodulation&#xD;
      and/or endothelial stabilization via binding and inactivation of endotoxin. Thus the&#xD;
      beneficial effects of albumin infusion described above are probably not only due to plasma&#xD;
      volume expansion but also to an improvement of various aspects of albumin function.&#xD;
&#xD;
      Albumin harbours two specific binding sites described by Sudlow: site I which binds large&#xD;
      heterocyclic compounds and dicarboxylic acids (such as bilirubin) and site II which binds&#xD;
      aromatic carboxylic compounds (such as benzodiazepines). Decreased binding of dansylsarcosine&#xD;
      (DS) - a model ligand for the benzodiazepin binding site II - was found in patients with&#xD;
      end-stage liver disease. Interestingly, extracorporeal albumin dialysis using the molecular&#xD;
      adsorbents recirculating system (MARS) has been found to improve DS binding, while no such&#xD;
      data exist for albumin infusion under the above-mentioned conditions.&#xD;
&#xD;
      Further examples for impaired albumin function in cirrhosis include alterations in fatty acid&#xD;
      binding (as estimated by electron paramagnetic resonance) and impaired metal binding&#xD;
      (measured as ischemia-modified albumin).&#xD;
&#xD;
      Impaired albumin function may be caused by oxidative albumin damage, which has been found in&#xD;
      several disease conditions including chronic liver failure. Three fractions of albumin can be&#xD;
      discerned according to the redox state of cysteine-34: non-oxidized human mercaptalbumin&#xD;
      (HMA) with Cys-34 as free sulfhydryl, reversibly oxidized human nonmercaptalbumin-1 (HNA1)&#xD;
      with Cys-34 as mixed disulfide, and irreversibly oxidized human nonmercaptalbumin-2 (HNA2)&#xD;
      with Cys-34 oxidized to sulfenic, sulfinic or sulfonic acid. The investigators of this study&#xD;
      have previously reported marked oxidative albumin damage in decompensated cirrhosis and even&#xD;
      more so in acute-on-chronic liver failure and these alterations were found to be related to&#xD;
      prognosis.&#xD;
&#xD;
      Small thiol compounds such as cysteine/cystin or glutathion interacting with the sulfhydryl&#xD;
      group at Cys-34 may change the oxidation state of albumin and may be oxidized/reduced&#xD;
      themselves. The role of small thiol compounds in various disease conditions and their&#xD;
      putative alterations following albumin infusion is currently unknown. Due to the complex&#xD;
      logistics of blood sample handling plasma thiol status is measured in a subset of 10 patients&#xD;
      only.&#xD;
&#xD;
      While free Cys-34 of albumin accounts for about 80% of the antioxidant capacity of human&#xD;
      plasma, both reversible and irreversible oxidation at this site will markedly reduce the&#xD;
      antioxidant function of albumin. Besides, irreversibly oxidized albumin causes intense&#xD;
      modifications of albumin structure and leads to marked alterations of albumin binding&#xD;
      function.&#xD;
&#xD;
      Interestingly, oxidative albumin modification observed in chronic liver failure was&#xD;
      paralleled by an impairment of albumin binding capacity as measured by DS binding. This&#xD;
      finding among others has led to the concept of effective albumin concentration, which may&#xD;
      further aggravate hypoalbuminemia observed in chronic liver failure.&#xD;
&#xD;
      The effect of albumin infusion on oxidative albumin modification and albumin function in&#xD;
      chronic liver failure is currently unknown.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 3, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Albumin oxidation status</measure>
    <time_frame>48 hours</time_frame>
    <description>changes in albumin oxidation status (HMA, HNA1, HNA2; percentage) due to albumin infusion measured by HPLC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>albumin binding capacity for dansylsarcosine</measure>
    <time_frame>48 hours</time_frame>
    <description>changes in albumin binding capacity (IC50) due to albumin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma renin activity</measure>
    <time_frame>48 h</time_frame>
    <description>changes in plasma renin activity (ELISA; uU/ml) due to albumin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma copeptin concentration</measure>
    <time_frame>48 h</time_frame>
    <description>changes in plasma copeptin concentration (ELISA; pmol/l) due to albumin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma thiol status</measure>
    <time_frame>48 h</time_frame>
    <description>changes in plasma thiol status (HPLC, umol/l) due to albumin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum endotoxin levels</measure>
    <time_frame>48 h</time_frame>
    <description>changes in serum endotoxin levels (measured by HEK blue LPS detection kit, IU/ml) due to albumin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil phagocytic capacity</measure>
    <time_frame>48 h</time_frame>
    <description>changes in neutrophil phagocytic capacity (flow cytometry; percentage FITC positive cells) due to albumin infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutrophil oxidative burst</measure>
    <time_frame>48 h</time_frame>
    <description>changes in neutrophil oxidative burst (flow cytometry; percentage FITC positive cells) due to albumin infusion</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Decompensated Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Albumin infusion</arm_group_label>
    <description>Patients with decompensated cirrhosis and an indication for routine human albumin infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human albumin</intervention_name>
    <description>Infusion of human albumin</description>
    <arm_group_label>Albumin infusion</arm_group_label>
    <other_name>Albumin</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, neutrophil granulocytes&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Forty consecutive patients receiving albumin infusions routinely in the above-mentioned&#xD;
        clinical conditions (paracentesis, hepatorenal syndrome, SBP) will be studied at the&#xD;
        Medical University of Graz.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Routine indication for albumin infusion&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Malignant ascites&#xD;
&#xD;
          -  Presence of hepatocellular carcinoma or advanced extrahepatic neoplasia&#xD;
&#xD;
          -  Nephrotic syndrome&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
&#xD;
          -  Albumin infusion &gt;80g within the last 48 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Rudofl E Stauber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

